# US 2025/0367306 A1 · Chimeric peptides for antisense delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367306 A1
- Document ID: US20250367306A1
- Status: Published application
- Kind: A1
- Application number: 19/233,984
- Filed: 2025-06-10
- Published: 2025-12-04
- Earliest claimed: 2018-03-16
- Assignees: Sarepta Therapeutics, Inc.; Massachusetts Institute of Technology
- Applicants: Sarepta Therapeutics, Inc.; Massachusetts Institute of Technology
- Inventors: Bradley L. PENTELUTE; Colin M. FADZEN; Rebecca L. HOLDEN; Justin M. WOLFE; Zi-Ning CHOO; Monica YAO; Gunnar J. HANSON
- Web page: https://patentgrep.com/patent/US20250367306A1

## CPC

- A61K 47/645: {Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT}
- A61K 47/6455: {Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids}
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/11: Antisense
- C12N 2310/314: Phosphoramidates
- C12N 2310/3233: Morpholino-type ring
- C12N 2310/3513: Protein; Peptide
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are oligonucleotides, chimeric peptides, and peptide-oligonucleotide-conjugates, the chimeric peptides and peptide-oligonucleotide-conjugates comprising at least two cell-penetrating peptides, wherein at least one of the cell-penetrating peptides is an amphipathic peptide and at least one of the cell-penetrating peptides is an oligoarginine peptide. The oligoarginine peptide comprises the sequence [(RYzR)x](SEQ ID NOs: 15-18), wherein R is arginine, Y is independently selected from aminohexanoic acid (X) or β-alanine (B). Also provided herein are methods of treating a muscle disease, a viral infection, or a bacterial infection in a subject in need thereof, comprising administering to the subject oligonucleotides, chimeric peptides, and peptide-oligonucleotide-conjugates comprising at least two cell-penetrating peptides, wherein at least one of the cell-penetrating peptides is an amphipathic peptide and at least one of the cell-penetrating peptides is an oligoarginine peptide described herein.

## Claims

### Claim 1

A chimeric peptide-oligonucleotide conjugate of Formula I:
or a pharmaceutically acceptable salt thereof,
wherein:
A′ is selected from —NHCH2C(O)NH2, —N(C1-6-alkyl)CH2C(O)NH2,
wherein
R5 is —C(O)(O-alkyl)x-OH, wherein x is 3-10 and each alkyl group is, independently at each occurrence, C2-6-alkyl,
or R5 is selected from —C(O)C1-6-alkyl, trityl, monomethoxytrityl, —(C1-6-alkyl)-R6, —(C1-6-heteroalkyl)-R6, aryl-R6, heteroaryl-R6, —C(O)O—(C1-6-alkyl)-R6, —C(O)O-aryl-R6, —C(O)O-heteroaryl-R6, and
wherein R6 is selected from OH, SH, and NH2, or R6 is O, S, or NH, each of which are covalently-linked to a solid support;
each R1 is independently selected from OH and —N(R3)(R4), wherein each R3 and R4 are, independently at each occurrence, —C1-6-alkyl;
each R2 is independently selected from H, a nucleobase, and a nucleobase functionalized with a chemical protecting-group, wherein the nucleobase, independently at each occurrence, comprises a C3-6-heterocyclic ring selected from pyridine, pyrimidine, triazinane, purine, and deaza-purine;
z is 8-40; and
E′ is selected from H, —C1-6-alkyl, —C(O)C1-6-alkyl, benzoyl, stearoyl, trityl, monomethoxytrityl, dimethoxytrityl, trimethoxytrityl,
wherein
Q is —C(O)(CH2)6C(O)— or —C(O)(CH2)2S2(CH2)2C(O)—;
R7 is —(CH2)2OC(O)N(R′)2, wherein R8 is —(CH2)6NHC(═NH)NH2;
L is —C(O)(CH2)1-6—C1-6-heteroaromatic-(CH2)1-6C(O), wherein L is covalently-linked by an amide bond to the amino-terminus of J;
J is 2, 3, 4, or 5 covalently-linked cell-penetrating peptides;
G is selected from H, —C(O)C1-6-alkyl, benzoyl, and stearoyl, wherein G is covalently-linked by an amide bond to the carboxy-terminus of J; and
wherein at least one of the following conditions is true:
1) A′ is
or 2) E′ is
wherein at least one of the cell-penetrating peptides is an amphipathic peptide and at least one of the cell-penetrating peptides is an oligoarginine peptide.

### Claim 2 (depends on 1)

The chimeric peptide-oligonucleotide conjugate of claim 1, or a pharmaceutically acceptable salt thereof, wherein J is 2, 3, 4, or 5 covalently-linked cell-penetrating peptides, and wherein the cell-penetrating peptides are independently an amphipathic peptide or an oligoarginine peptide.

### Claim at position 3

3-4. (canceled)

### Claim 5 (depends on 1)

The chimeric peptide-oligonucleotide conjugate of claim 1, or a pharmaceutically acceptable salt thereof, wherein J is 3, 4, or 5 covalently-linked cell-penetrating peptides.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The chimeric peptide-oligonucleotide conjugate of claim 1, or a pharmaceutically acceptable salt thereof, wherein J is two covalently-linked cell-penetrating peptides, and wherein one of the cell-penetrating peptides is an amphipathic peptide and one of the cell-penetrating peptides is an oligoarginine peptide.

### Claim 8 (depends on 1)

The chimeric peptide-oligonucleotide conjugate of claim 1, or a pharmaceutically acceptable salt thereof, wherein J is two covalently-linked cell-penetrating peptides, wherein the two cell-penetrating peptides comprise one amphipathic peptide and one oligoarginine peptide, and wherein the oligoarginine peptide is the C-terminus of J and the amphipathic peptide is the N-terminus of J.

### Claim 9 (depends on 1)

The chimeric peptide-oligonucleotide conjugate of claim 1, or a pharmaceutically acceptable salt thereof, wherein J is two covalently-linked cell-penetrating peptides that are covalently-linked by an amide bond.

### Claim 10 (depends on 1)

The chimeric peptide-oligonucleotide conjugate of claim 1, or a pharmaceutically acceptable salt thereof, wherein the oligarginine peptide comprises the sequence [(RBR)(RXR)]x (SEQ ID NO: 7 and 9), wherein R is arginine, X is aminohexanoic acid, B is B-alanine, and x is 1 or 2.

### Claim 11 (depends on 1)

The chimeric peptide-oligonucleotide conjugate of claim 1, or a pharmaceutically acceptable salt thereof, wherein the oligarginine peptide comprises the sequence [(RXR)(RBR)]x (SEQ ID NO: 8 and 10), wherein R is arginine, X is aminohexanoic acid, B is B-alanine, and x is 1 or 2.

### Claim 12 (depends on 11)

The chimeric peptide-oligonucleotide conjugate of claim 11, or a pharmaceutically acceptable salt thereof, wherein the oligoarginine peptide is [(RXR)(RBR)]2 (SEQ ID NO: 10) (Bpep).

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The chimeric peptide-oligonucleotide conjugate of claim 1, or a pharmaceutically acceptable salt thereof, wherein the hydrophobic segment comprises a sequence of 2 to 10 amino acids independently selected from glycine, isoleucine, alanine, valine, leucine, phenylalanine or tryptophan.

### Claim 15 (depends on 1)

The chimeric peptide-oligonucleotide conjugate of claim 1, or a pharmaceutically acceptable salt thereof, wherein the hydrophophilic segment comprises a sequence of 2 to 20 amino acids independently selected from arginine, lysine, glutamine, asparagine, histidine, serine, threonine, tryptophan, alanine, isoleucine, leucine, methionine, phenylalanine, valine, proline, or glycine, wherein the hydrophilic peptidyl segment comprises at least one non-hydrophobic amino acid.

### Claim 16 (depends on 1)

The chimeric peptide-oligonucleotide conjugate of claim 1, or a pharmaceutically acceptable salt thereof, wherein the amphipathic peptide is pVEC, penetratin, or melittin.

### Claim at position 16

17-18. (canceled)

### Claim 19 (depends on 1)

The chimeric peptide-oligonucleotide conjugate of claim 1, or a pharmaceutically acceptable salt thereof, wherein J is penetratin-Bpep (RQIKIWFQNR RMKWKKRXRR BRRXRRBR) (SEQ ID NO: 1), pVEC-Bpep (LLIILRRRIR KQAHAHSKRX RRBRRXRRBR) (SEQ ID NO: 2), or melittin-Bpep (GIGAVLKVLT TGLPALISWI KRKRQQRXRR BRRXRRBR) (SEQ ID NO: 3).

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The chimeric peptide-oligonucleotide conjugate of claim 1, or a pharmaceutically acceptable salt thereof, wherein E′ is selected from H, and

### Claim 22 (depends on 1)

The chimeric peptide-oligonucleotide conjugate of claim 1, or a pharmaceutically acceptable salt thereof, wherein
A′ is selected from

### Claim at position 21

23-24. (canceled)

### Claim 25 (depends on 1)

The chimeric peptide-oligonucleotide conjugate of claim 1, or a pharmaceutically acceptable salt thereof, wherein A′ is
and
E′ is selected from H, —C(O)CH3, trityl, 4-methoxytrityl, benzoyl, and stearoyl.

### Claim 26 (depends on 1)

The chimeric peptide-oligonucleotide conjugate of claim 1, or a pharmaceutically acceptable salt thereof, wherein the peptide-oligonucleotide conjugate of Formula I is a peptide-oligonucleotide conjugate selected from:
wherein E′ is selected from H, C1-6-alkyl, —C(O)CH3, benzoyl, and stearoyl.

### Claim 27 (depends on 26)

The chimeric peptide-oligonucleotide conjugate of claim 26, or a pharmaceutically acceptable salt thereof, wherein the peptide-oligonucleotide conjugate is of the formula (Ia).

### Claim at position 25

28-29. (canceled)

### Claim 30 (depends on 1)

The chimeric peptide-oligonucleotide conjugate of claim 1, or a pharmaceutically acceptable salt thereof, wherein each R2 is a nucleobase, independently at each occurrence, selected from adenine, guanine, cytosine, 5-methyl-cytosine, thymine, uracil, and hypoxanthine.

### Claim at position 27

31-32. (canceled)

### Claim 33 (depends on 1)

The chimeric peptide-oligonucleotide conjugate of claim 1, or a pharmaceutically acceptable salt thereof, wherein G is selected from H, C(O)CH3, benzoyl, and stearoyl.

### Claim at position 29

34-39. (canceled)

### Claim 40 (depends on 1)

A chimeric composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

### Claim 41 (depends on 1)

A method of treating a disease in a subject in need thereof, the method comprising administering a therapeutically effective amount of the chimeric composition of claim 1 to the subject.

### Claim 42

(canceled)

### Claim 43 (depends on 41)

The method of claim 41, where the neuromuscular disease is Duchenne muscular dystrophy.

### Claim 44

A chimeric peptide-oligonucleotide conjugate of Formula I:
or a pharmaceutically acceptable salt thereof,
wherein:
A′ is selected from —NHCH2C(O)NH2, —N(C1-6-alkyl)CH2C(O)NH2,
wherein
R5 is —C(O)(O-alkyl)x-OH, wherein x is 3-10 and each alkyl group is, independently at each occurrence, C2-6-alkyl,
or R5 is selected from —C(O)C1-6-alkyl, trityl, monomethoxytrityl, —(C1-6-alkyl)-R6, —(C1-6-heteroalkyl)-R6, aryl-R6, heteroaryl-R6, —C(O)O—(C1-6-alkyl)-R6, —C(O)O-aryl-R6, —C(O)O— heteroaryl-R6, and
wherein R6 is selected from OH, SH, and NH2, or R6 is O, S, or NH, each of which are covalently-linked to a solid support;
each R1 is independently selected from OH and —N(R3)(R4), wherein each R3 and R4 are, independently at each occurrence, —C1-6-alkyl;
each R2 is independently selected from H, a nucleobase, and a nucleobase functionalized with a chemical protecting-group, wherein the nucleobase, independently at each occurrence, comprises a C3-6-heterocyclic ring selected from pyridine, pyrimidine, triazinane, purine, and deaza-purine;
z is 8-40; and
E′ is selected from H, —C1-6-alkyl, —C(O)C1-6-alkyl, benzoyl, stearoyl, trityl, monomethoxytrityl, dimethoxytrityl, trimethoxytrityl,
wherein
Q is —C(O)(CH2)6C(O)— or —C(O)(CH2)2S2(CH2)2C(O)—;
R7 is —(CH2)2OC(O)N(R′)2, wherein R8 is —(CH2)6NHC(═NH)NH2;
L is —C(O)(CH2)1-6—C1-6-heteroaromatic-(CH2)1-6C(O), wherein L is covalently-linked by an amide bond to the amino-terminus of J;
J is Bpep-Bpep (RXRRBRRXRR BRRXRRBRRX RRBR) (SEQ ID NO: 4);
G is selected from H, —C(O)C1-6-alkyl, benzoyl, and stearoyl, wherein G is covalently-linked by an amide bond to the carboxy-terminus of J; and
wherein at least one of the following conditions is true:
1) A′ is
or 2) E′ is
